Trial Information

Summary: Study of Epratuzumab in Systemic Lupus Erythematosus

An Open-Label Re-Treatment Trial for Patients Previously Randomized Into the SL0003 and SL0004, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studies of Epratuzumab in Patients With Systemic Lupus Erythematosus

Epratuzumab is an investigational antibody designed to help treat SLE. The purpose of the study is to obtain additional long-term information regarding the safety and efficacy of continued maintenance-cycle administrations of epratuzumab

Inclusion Criteria:

• Must have participated in SL0003 or SL0004 and benefitted from participation in those studies

Exclusion Criteria:

• Development of toxicity to epratuzumab
• Significant protocol deviations during the SL0003 or SL0004 studies
• Evidence of significant infection

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:43:08 AM